Adagrasib versus docetaxel in KRAS(G12C)-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Barlesi F
  • Yao W
  • Duruisseaux M
  • Doucet L
  • Martínez AA
  • Gregorc V
  • Lu S
  • De Bondt C
  • de Marinis F
  • Linardou H
  • Kim YC
  • Jotte R
  • Felip E
  • Lo Russo G
  • Reck M
  • Michenzie MF
  • Yang W
  • Meade JN
  • Korytowsky B
  • Mok TSK
  • KRYSTAL-12 Investigators

Grupos

Abstract

BACKGROUND: Adagrasib is a KRAS(G12C) inhibitor that demonstrated promising activity against KRAS(G12C)-mutated advanced non-small-cell lung cancer (NSCLC) in a phase 2 trial. Here we aimed to compare the efficacy and safety of adagrasib versus docetaxel in patients with KRAS(G12C)-mutated advanced NSCLC previously treated with chemotherapy and immunotherapy. METHODS: KRYSTAL-12 is a randomised, multicentre, open-label, phase 3 trial conducted at 230 centres in 22 countries. Patients with Kirsten rat sarcoma viral oncogene homologue (KRAS)(G12C)-mutated locally advanced or metastatic NSCLC, who had previously received both platinum-based chemotherapy and anti-programmed cell death protein 1 or anti-programmed death ligand 1 therapy, were randomly allocated in a 2:1 ratio to receive 600 mg adagrasib (twice a day orally) or 75 mg/m(2) docetaxel (every 3 weeks intravenously) using a centralised interactive web response system. Randomisation was stratified by region (non-Asia-Pacific vs Asia-Pacific) and previous treatment (sequential vs concurrent chemotherapy or immunotherapy). Treatment continued until disease progression, unacceptable toxicity, investigator or patient decision, or death. The primary endpoint was progression-free survival assessed by blinded independent central review in all randomised patients (intention-to-treat [ITT] population). Safety was assessed in all treated patients. This trial is registered at ClinicalTrials.gov (NCT04685135), and is active but no longer recruiting. FINDINGS: Between Feb 23, 2021, and Nov 16, 2023, 453 patients were randomly allocated to receive adagrasib (301 [66%]) or docetaxel (152 [34%]). In each group, 298 (99%) patients received adagrasib and 140 (92%) received docetaxel. In the ITT population (median follow-up 7·2 months [95% CI 5·8-8·7]), median progression-free survival was 5·5 months (95% CI 4·5-6·7) with adagrasib and 3·8 months (95% CI 2·7-4·7) with docetaxel (hazard ratio 0·58 [95% CI 0·45-0·76]; p<0·0001). Grade 3 and above treatment-related adverse events occurred in 140 (47%) of 298 patients treated with adagrasib and 64 (46%) of 140 with docetaxel. There were four (1%) treatment-related deaths in the adagrasib group and one (1%) treatment-related death in the docetaxel group. INTERPRETATION: Adagrasib demonstrated a statistically significant improvement in progression-free survival over docetaxel in patients with previously treated KRAS(G12C)-mutated NSCLC, without new safety signals. FUNDING: Mirati Therapeutics, a Bristol Myers Squibb company.

Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.

Datos de la publicación

ISSN/ISSNe:
0140-6736, 1474-547X

LANCET  ELSEVIER SCIENCE INC

Tipo:
Article
Páginas:
615-626
PubMed:
40783289
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
15,652 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 59

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Acetonitriles; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); Pyrimidines; adagrasib; anti programmed cell death protein 1; antibody; docetaxel; kirsten rat sarcoma viral oncogene; peptides and proteins; unclassified drug; acetonitrile derivative; adagrasib; antineoplastic agent; docetaxel; KRAS protein, human; piperazine derivative; protein p21; pyrimidine derivative; adult; aged; Article; brain metastasis; chemotherapy; controlled study; disease exacerbation; drug efficacy; drug safety; European Quality of Life 5 Dimensions 5 Level questionnaire; female; gene mutation; human; immunotherapy; major clinical study; male; multicenter study; non small cell lung cancer; overall survival; phase 3 clinical trial; progression free survival; randomized controlled trial; clinical trial; comparative study; drug therapy; genetics; l

Cita

Compartir